Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas.
Kwang-Soo KimKarl HabashyAndrew GouldJunfei ZhaoHinda NajemChristina AmideiRuth SagantyVíctor A ArrietaCrismita DmelloLi ChenDaniel Y ZhangBrandyn CastroLeah BillinghamDaniel LeveyOlivia HuberMarilyn MarquesDavid A SavitskyBenjamin M MorinMiguel MuzzioMichael CanneyCraig HorbinskiPeng ZhangJason MiskaSurya PadneyBin ZhangRaúl RabadánJoanna J PhillipsNicholas ButowskiAmy B HeimbergerJian HuRoger StuppDhan ChandCatalina Lee-ChangAdam M SonabendPublished in: Neuro-oncology (2024)
Our findings demonstrate that FcE-aCTLA-4 promotes robust immunomodulatory and anti-tumor effects in murine gliomas and is significantly enhanced when combined with anti-PD-1, doxorubicin, and LIPU/MB. We are currently investigating this combinatory strategy in a clinical trial (clinicaltrials.gov NCT05864534).